biotechs

Stem cell company Intellicell facing new financial wrinkles

Intellicell

It’s difficult to make it as a biotech company, I would say stem cell biotechs in general may have an even rougher time, and one such company,  Intellicell (Intellicell Biosciences, Inc), is showing a number of signs of distress in my opinion. An online financial tool predicts the probability of companies going bankrupt within the next …

Stem cell company Intellicell facing new financial wrinkles Read More »

Interview with Gary Rabin of Advanced Cell Technology (ACT)

Gary-Rabin-headshot-formatted-5.25

One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms of preliminary safety data. However, ACT has much more in the pipeline including potentially iPS …

Interview with Gary Rabin of Advanced Cell Technology (ACT) Read More »

Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million

Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are most pleased about this financing agreement, as it has a number of notable benefits for the company,” commented Gary Rabin, chairman and CEO of …

Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million Read More »

The stem cell gestalt of Geron Goodbye and the future of ACT

Geron-300x2212

Last year one of the biggest events in the stem cell field was biotech Geron punting its embryonic stem cell (ESC) program. Much consternation followed. Some folks opposed to ESCs happily pronounced ESC research dead. Some folks in favor of ESC thought the world was ending a year early. Others tried to look on the …

The stem cell gestalt of Geron Goodbye and the future of ACT Read More »

The Scarlett letter? What the experts really think about Geron

The grapevine is afire with the Geron news and there are many interpretations out there of what it means and why it happened. Based on several accounts from folks who remain anonymous, here is the most probable prediction of what happened to lead us to yesterday’s announcement. Geron has been worried for a long time …

The Scarlett letter? What the experts really think about Geron Read More »

Bad news as Geron to quit hESC SCI trial for financial reasons

Geron-300x2212

Reportedly, Geron has decided to only focus on cancer research and for financial reasons has shut down its hESC trial for spinal cord injury. This is a very sad day for stem cell science. (Update in 2020: the firm still exists, but is working in different areas. The stock has struggled.) No more spinal cord …

Bad news as Geron to quit hESC SCI trial for financial reasons Read More »

Advanced Cell Technology and Geron: allies or competitors?

Geron-300x2212

Two companies, Advanced Cell Technology (ACT) and Geron, both HQ’d here in California, have FDA-approved early stage clinical trials in the works. Geron’s trial has already started and reportedly now has enrolled at least two patients. The trial is of course for the safety of Geron’s GRNOPC1 oligodendrocyte product made from human ES cells for …

Advanced Cell Technology and Geron: allies or competitors? Read More »

Great news: FDA gives ACT the green light bringing hope to millions of people with blindness

advanced-cell-technology

The FDA has given Advanced Cell Technology (ACT) the go ahead to begin their clinical trial using retinal progenitor cells derived from hESC by clearing the company’s IND application, bringing hope to those with vision loss and even blindness. The trial will be a combined Phase I/II to treat Stargardt’s Macular Dystrophy and has huge …

Great news: FDA gives ACT the green light bringing hope to millions of people with blindness Read More »